Literature DB >> 9208156

Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study.

P Sacerdote1, B Manfredi, P Mantegazza, A E Panerai.   

Abstract

1. Although it is well known that morphine induces significant immunosuppression, the potential immunosuppressive activity of morphine derived drugs commonly used in the treatment of pain (codeine, hydromorphone, oxycodone) has never been evaluated. 2. We evaluated in the mouse the effect of the natural opiates (morphine and codeine) and synthetic derivatives (hydromorphone, oxycodone, nalorphine, naloxone and naltrexone) on antinociceptive thresholds and immune parameters (splenocyte proliferation, Natural Killer (NK) cell activity and interleukin-2 (IL-2) production). 3. Morphine displayed a potent immunosuppressive effect that was not dose-related to the antinociceptive effect, codeine possessed a weak antinociceptive effect and limited immunosuppressive activity; nalorphine, a mu-antagonist and kappa-agonist, exerted a potent immunosuppressive effect, but had very weak antinociceptive activity. The pure kappa-antagonist nor-BNI antagonized the antinociceptive, but not the immunosuppressive effect of nalorphine. 4. Hydromorphone and oxycodone, potent antinociceptive drugs, were devoid of immunosuppressive effects. 5. The pure antagonists naloxone and naltrexone potentiated immune responses. 6. Our data indicate that the C6 carbonyl substitution, together with the presence of a C7-8 single bond potentiates the antinociceptive effect, but abolishes immunosuppression (hydromorphone and oxycodone). 7. The single substitution of an allyl on the piperidinic ring resulted in a molecule that antagonized the antinociceptive effect but maintained the immunosuppressive effect. 8. Molecules that carry modifications of C6, the C7-8 bond and C14, together with an allyl or caboxymethyl group on the piperidinic ring antagonized both the antinociceptive and the immunosuppressive effect of opiates and were themselves immunostimulants.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9208156      PMCID: PMC1564723          DOI: 10.1038/sj.bjp.0701138

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  51 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  Influence of endogenous opioid systems on T lymphocytes as assessed by the knockout of mu, delta and kappa opioid receptors.

Authors:  Ali G Karaji; David Reiss; Audrey Matifas; Brigitte L Kieffer; Claire Gavériaux-Ruff
Journal:  J Neuroimmune Pharmacol       Date:  2011-09-22       Impact factor: 4.147

Review 3.  Opioids and the immune system - friend or foe.

Authors:  Lisanne Mirja Plein; Heike L Rittner
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

4.  The use of prescribed opioid analgesics & the risk of serious infections.

Authors:  Andrew D Wiese; Carlos G Grijalva
Journal:  Future Microbiol       Date:  2018-06-13       Impact factor: 3.165

Review 5.  Immunosuppressive effects of opioids--clinical relevance.

Authors:  Alexander Brack; Heike L Rittner; Christoph Stein
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-05       Impact factor: 4.147

Review 6.  To Treat or Not to Treat: The Effects of Pain on Experimental Parameters.

Authors:  Norman C Peterson; Elizabeth A Nunamaker; Patricia V Turner
Journal:  Comp Med       Date:  2017-12-01       Impact factor: 0.982

Review 7.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

8.  Opiates and the development of post-injury complications: a review.

Authors:  Martin G Schwacha
Journal:  Int J Clin Exp Med       Date:  2008-01-20

9.  Effects of morphine and fentanyl on 5-fluorouracil sensitivity in human colon cancer HCT116 cells.

Authors:  Yasumitsu Nomura; Yoshitaka Kawaraguchi; Hiroshi Sugimoto; Hitoshi Furuya; Masahiko Kawaguchi
Journal:  J Anesth       Date:  2013-10-05       Impact factor: 2.078

10.  Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation.

Authors:  David Philippe; Laurent Dubuquoy; Hervé Groux; Valérie Brun; Myriam Tran Van Chuoï-Mariot; Claire Gaveriaux-Ruff; Jean-Frédéric Colombel; Brigitte L Kieffer; Pierre Desreumaux
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.